Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure | Zendy

Christie Joya | Zendy; Seung Won | Zendy; Christina Schofield | Zendy; Tahaniyat Lalani | Zendy; Ryan C. Maves | Zendy; Karl Kronmann | Zendy; Robert Deiss | Zendy; Jason F. Okulicz | Zendy; Brian K. Agan | Zendy; Anuradha Ganesan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure

Author(s) -

Christie Joya,

Seung Won,

Christina Schofield,

Tahaniyat Lalani,

Ryan C. Maves,

Karl Kronmann,

Robert Deiss,

Jason F. Okulicz,

Brian K. Agan,

Anuradha Ganesan

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz129

Subject(s) - viremia , medicine , hazard ratio , regimen , confidence interval , proportional hazards model , viral load , antiretroviral therapy , reverse transcriptase inhibitor , gastroenterology , human immunodeficiency virus (hiv) , immunology

Whether persistent low-level viremia (pLLV) predicts virologic failure (VF) is unclear. We used data from the US Military HIV Natural History Study (NHS), to examine the association of pLLV and VF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research